September's Clovertex Target of the Month is GPR61 following Pfizer's recent publication concerning...
In August 2023, the GABAA receptor is highlighted our 'Clovertex Target of the Month' as the drug target behind the FDA's recent approval of Zurzuvae (zuranolone) for postpartum depression (PPD) treatment. The topic of PPD is one that hits close to home for many, making this development particularly significant.
The GABAA receptor, an integral neurotransmitter receptor in the central nervous system, mediates inhibitory synaptic transmission. It plays a pivotal role in mood regulation, making it a prime target for drugs treating various depressive disorders. Zurzuvae's action on this receptor offers a novel approach to PPD treatment, transitioning away from IV injections to a more accessible oral medication.
Clinical trials showcased Zurzuvae's efficacy, with PPD-diagnosed women displaying notable improvements in depressive symptoms compared to placebo groups. These positive effects persisted for weeks after the treatment. In light of these advancements, the GABA_A receptor earns its title as the 'Clovertex Drug Target of the Month'. The protein model rendering depicts the cryo-EM structure of the human GABA_A receptor alpha1-beta2-gamma2 subtype in complex with GABA plus allopregnanolone (PDB 8SI9).
About Clovertex
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
Useful links
1. FDA Approves First Oral Treatment for Postpartum Depression
2. Clovertex website
